目次

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Aplastic Anemia - Overview
Aplastic Anemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Aplastic Anemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Aplastic Anemia - Companies Involved in Therapeutics Development
Aplastic Anemia - Drug Profiles
Aplastic Anemia - Dormant Projects
Aplastic Anemia - Discontinued Products
Aplastic Anemia - Product Development Milestones
Featured News & Press Releases
May 12, 2021: Regen Biopharma announces consulting agreement with Biotech Research Group
Jan 11, 2021: Gamida Cell to present full data from phase 3 Study of omidubicel at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
Dec 14, 2020: Gamida Cell provides regulatory update on Biologics License Application for Omidubicel
Dec 09, 2020: Gamida Cell provides pipeline update, including detailed results of pivotal phase 3 clinical study of omidubicel, and prepares to start BLA submission by end of 2020
Nov 04, 2020: Gamida cell announces data on omidubicel to be presented at 62nd ASH Annual Virtual Meeting
Apr 21, 2020: Hemogenyx Pharmaceuticals announces approval and issuance of European Hu-PHEC Patent
Feb 11, 2020: Hemogenyx Pharmaceuticals: Approval and issuance of U.S. Hu-PHEC Patent
Oct 17, 2019: The CHMP adopted a negative opinion recommending the refusal of a marketing authorisation for Revolade (eltrombopag)
Aug 01, 2019: Health ministry to reimburse Novartis' Revolade treating severe aplastic anemia
Jun 28, 2019: Refusal of a change to the marketing authorisation for Revolade (eltrombopag)
Jun 25, 2019: Novartis has requested a re-examination of EMA's opinion on Revolade
Jun 18, 2019: Kyowa Hakko Kirin receives the partial change approval of Romiplate for Aplastic Anemia in Japan
May 11, 2019: Novartis issues voluntary nationwide recall of Promacta 12.5 mg for oral suspension due to potential peanut contamination
Feb 21, 2019: Gamida cell presents initial data from phase 1/2 study of NiCord in severe aplastic anemia at 2019 TCT Annual Meeting
Feb 14, 2019: Gamida Cell to host conference call and webcast to review data from NiCord program being presented at 2019 TCT Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Aplastic Anemia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Aplastic Anemia - Pipeline by Acceleron Pharma Inc, 2022
Aplastic Anemia - Pipeline by Amgen Inc, 2022
Aplastic Anemia - Pipeline by ASC Therapeutics Inc, 2022
Aplastic Anemia - Pipeline by Bellicum Pharmaceuticals Inc, 2022
Aplastic Anemia - Pipeline by BioLineRx Ltd, 2022
Aplastic Anemia - Pipeline by Cell Source Inc, 2022
Aplastic Anemia - Pipeline by Cellenkos Inc, 2022
Aplastic Anemia - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Aplastic Anemia - Pipeline by Gamida Cell Ltd, 2022
Aplastic Anemia - Pipeline by Hangzhou Zede Pharmaceutical Technology Co Ltd, 2022
Aplastic Anemia - Pipeline by HemoGenyx Pharmaceuticals Plc, 2022
Aplastic Anemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Aplastic Anemia - Pipeline by Novartis AG, 2022
Aplastic Anemia - Pipeline by Ono Pharmaceutical Co Ltd, 2022
Aplastic Anemia - Pipeline by Pfizer Inc, 2022
Aplastic Anemia - Pipeline by Regen BioPharma Inc, 2022
Aplastic Anemia - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Aplastic Anemia - Dormant Projects, 2022
Aplastic Anemia - Discontinued Products, 2022

List of Figures
Number of Products under Development for Aplastic Anemia, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022